A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

NCT03048136 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business objective has changed

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb